Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 3
1993 1
1998 1
2002 1
2003 2
2004 3
2005 4
2006 4
2007 5
2008 3
2009 5
2010 7
2011 2
2012 9
2013 11
2014 12
2015 16
2016 19
2017 17
2018 14
2019 13
2020 19
2021 21
2022 17
2023 19
2024 6
2025 9
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

219 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean hu fc[au] (176 results)?
Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trial.
Zhu FC, Zhong GH, Huang WJ, Chu K, Zhang L, Bi ZF, Zhu KX, Chen Q, Zheng TQ, Zhang ML, Liu S, Xu JB, Pan HX, Sun G, Zheng FZ, Zhang QF, Yi XM, Zhuang SJ, Huang SJ, Pan HR, Su YY, Wu T, Zhang J, Xia NS. Zhu FC, et al. Lancet Infect Dis. 2023 Nov;23(11):1313-1322. doi: 10.1016/S1473-3099(23)00275-X. Epub 2023 Jul 17. Lancet Infect Dis. 2023. PMID: 37475116 Clinical Trial.
The vaccines-associated Arthus reaction.
Peng B, Wei M, Zhu FC, Li JX. Peng B, et al. Among authors: zhu fc. Hum Vaccin Immunother. 2019;15(11):2769-2777. doi: 10.1080/21645515.2019.1602435. Epub 2019 May 3. Hum Vaccin Immunother. 2019. PMID: 30945978 Free PMC article.
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.
Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, Li JX, Yang BF, Wang L, Wang WJ, Wu SP, Wang Z, Wu XH, Xu JJ, Zhang Z, Jia SY, Wang BS, Hu Y, Liu JJ, Zhang J, Qian XA, Li Q, Pan HX, Jiang HD, Deng P, Gou JB, Wang XW, Wang XH, Chen W. Zhu FC, et al. Lancet. 2020 Aug 15;396(10249):479-488. doi: 10.1016/S0140-6736(20)31605-6. Epub 2020 Jul 20. Lancet. 2020. PMID: 32702299 Free PMC article. Clinical Trial.
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.
Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, Wu SP, Wang BS, Wang Z, Wang L, Jia SY, Jiang HD, Wang L, Jiang T, Hu Y, Gou JB, Xu SB, Xu JJ, Wang XW, Wang W, Chen W. Zhu FC, et al. Lancet. 2020 Jun 13;395(10240):1845-1854. doi: 10.1016/S0140-6736(20)31208-3. Epub 2020 May 22. Lancet. 2020. PMID: 32450106 Free PMC article. Clinical Trial.
COVID-19 immunisation strategies for adolescents.
Wang WX, Zhu FC. Wang WX, et al. Among authors: zhu fc. Lancet Infect Dis. 2025 Feb;25(2):143-144. doi: 10.1016/S1473-3099(24)00563-2. Epub 2024 Sep 24. Lancet Infect Dis. 2025. PMID: 39332419 No abstract available.
[Research progress of maternal immunization].
Zhang DW, Li JX, Hu JL, Peng BZ, Zhu FC. Zhang DW, et al. Among authors: zhu fc. Zhonghua Yu Fang Yi Xue Za Zhi. 2019 May 6;53(5):534-539. doi: 10.3760/cma.j.issn.0253-9624.2019.05.020. Zhonghua Yu Fang Yi Xue Za Zhi. 2019. PMID: 31091616 Review. Chinese.
The COVID-19 Vaccine in Clinical Trials: Where Are We Now?
Jiang HD, Li JX, Zhang P, Huo X, Zhu FC. Jiang HD, et al. Among authors: zhu fc. Infect Dis Immun. 2021 Apr 20;1(1):43-51. doi: 10.1097/ID9.0000000000000003. eCollection 2021 Apr. Infect Dis Immun. 2021. PMID: 38630107 Free PMC article. Review.
219 results